The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Immunotherapeutic approaches for MCL patients who progress following BTKi treatment
Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, outlines the immunotherapeutic options for patients with mantle cell lymphoma (MCL) who progress on BTK inhibitors (BTKi). Recent developments include FDA-approved brexucabtagene autoleucel, along with bispecific antibodies and antibody-drug conjugates like zilovertamab vedotin. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: BMS/Celgene, Novartis, Genentech, BioInvent, Lam Therapeutics, Takeda, AstraZeneca, Loxo/Lilly
Consultancy: ADCT, AstraZeneca, Abbvie, Janssen, BeiGene, Loxo/Lilly
